Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611000671965
Ethics application status
Approved
Date submitted
1/07/2011
Date registered
4/07/2011
Date last updated
8/04/2014
Type of registration
Prospectively registered
Titles & IDs
Public title
The Effect of Oxytocin on Cognitive Rigidity and Social Anxiety in Eating Disorders
Query!
Scientific title
The Effect of Oxytocin on Cognitive Rigidity and Social Anxiety in Eating Disorders: A Randomized Placebo
Controlled Trial of Oxytocin in the Treatment of Anorexia Nervosa
Query!
Secondary ID [1]
262410
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Anorexia Nervosa
268205
0
Query!
Condition category
Condition code
Mental Health
268335
268335
0
0
Query!
Eating disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Oxytocin nasal spray - Participants will receive 2 daily doses of oxytocin (36 International Units per day) for the duration of the entire trial, 6 weeks. The oxytocin will be administered in 2 puffs, one to each nostril, twice a day, each puff containing 9 International Units of oxytocin.
Query!
Intervention code [1]
266791
0
Treatment: Drugs
Query!
Comparator / control treatment
Placebo saline nasal spray - Participants will receive 2 daily doses of the placebo saline solution for the duration of the entire trial, 6 weeks. The placebo will be administered in the exact same way as the oxytocin (i.e. 2 puffs, one to each nostril, twice a day)
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
269104
0
Level of social anxiety measured by The Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987)
Query!
Assessment method [1]
269104
0
Query!
Timepoint [1]
269104
0
Measured pre treatment (Week 0) and post treatment (week 6)
Query!
Primary outcome [2]
279872
0
Level of cognitive rigidity measured by the Brixton Task (Burgess and Shallice, 1997)
Query!
Assessment method [2]
279872
0
Query!
Timepoint [2]
279872
0
Measured pre treatment (Week 0) and post treatment (week 6)
Query!
Secondary outcome [1]
276943
0
Changes in cognitive functioning assessed using a range of measures including: 1. The Eye-Gaze Task (Guastella, Mitchell, & Dadds, 2008) 2. Reading the Mind in the Eyes Test (RMET, Baron-Cohen et al 2001) 3. Wisconsin Card Sorting Test (Heaton et al, 1993) 4. The Pictorial/Emotional Stroop task (Ashwin et al. 2006; Williams et al. 1996) 5. The Working Alliance Inventory-Short Form (Therapist and Participant versions) (Hatcher & Gillaspy, 2006) 6. The Obsessive-Compulsive Inventory-Revised (OCI-R; Foa et al., 2002)
Query!
Assessment method [1]
276943
0
Query!
Timepoint [1]
276943
0
Measured at four time points - pre-treatment (week 0), week 3, post treatment (week 6) and three week follow up at week 9.
Query!
Eligibility
Key inclusion criteria
Participants who meet DSM-IV diagnostic criteria for Anorexia Nervosa will be included in the study. Participants suffering from common comorbidities of depression and anxiety and Axis II disorders will be included in the study.
Query!
Minimum age
16
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Participants will be exluded from the trial if they are suffering from any other major conditions, apart from those related to anorexia nervosa (i.e. common comorbidities of depression, anxiety and Axis II disorders)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Persons attending day programs, inpatients and outpatients
with Anorexia Nervosa will be approached to participate in the study. Informed consent procedures will be followed in
recruiting persons to the study, parental consent will be sought for individuals 16 to 18 years of age. All potential participants in the study will have been screened using the Eating Disorder Examination 16th Edition (EDE 16.0D) to confirm diagnosis. Participants will be randomly assigned to the Oxytocin or Placebo Treatment by computer program. A
member of the Brain and Mind Research Institute, along side a compouding chemist, will be responsible for the random allocation of participants. Nobody at the data collection site will be aware of the group to which the participant has been allocated to.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation by using a randomisation table created by computer software (i.e., computerised sequence generation).
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
22/11/2011
Query!
Actual
6/01/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
12/12/2013
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
80
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
2300
0
Northside Clinic Private Hospital - Greenwich
Query!
Recruitment postcode(s) [1]
4176
0
2050
Query!
Funding & Sponsors
Funding source category [1]
267357
0
Charities/Societies/Foundations
Query!
Name [1]
267357
0
The Butterfly Foundation
Query!
Address [1]
267357
0
The Butterfly Foundation
103 Alexander Street Crows Nest NSW 2065
Query!
Country [1]
267357
0
Australia
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
The Centre for Eating and Dieting Disorders (CEDD)
Query!
Address
Derwent House, 1 - 3 Derwent St,
Glebe, NSW, 2031
Query!
Country
Australia
Query!
Secondary sponsor category [1]
266425
0
Hospital
Query!
Name [1]
266425
0
SYDNEY LOCAL HEALTH DISTRICT (SLHD)
Query!
Address [1]
266425
0
c/- RESEARCH DEVELOPMENT OFFICE, RPAH
MISSENDEN ROAD, CAMPERDOWN, NSW, 2050
Query!
Country [1]
266425
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
269335
0
Sydney South West Area Health Service (SSWAHS) Royal Prince Alfred Hospital Ethics Review Committee (RPAH Zone)
Query!
Ethics committee address [1]
269335
0
C/- Research Development Office Level 3, Building 92 Royal Prince Alfred Hospital Missenden Rd CAMPERDOWN NSW 2050
Query!
Ethics committee country [1]
269335
0
Australia
Query!
Date submitted for ethics approval [1]
269335
0
27/07/2011
Query!
Approval date [1]
269335
0
21/09/2011
Query!
Ethics approval number [1]
269335
0
Protocol Number X11-0153 and HREC/11/RPAH/220
Query!
Ethics committee name [2]
272076
0
Northside Group Ethics Committee
Query!
Ethics committee address [2]
272076
0
Northside Clinic, 2 Greenwich Rd GREENWICH NSW 2065
Query!
Ethics committee country [2]
272076
0
Australia
Query!
Date submitted for ethics approval [2]
272076
0
29/07/2011
Query!
Approval date [2]
272076
0
04/10/2011
Query!
Ethics approval number [2]
272076
0
Protocol Number X11-0153
Query!
Summary
Brief summary
The main purpose of this study is to ascertain whether inhaled oxytocin might have therapeutic potential in reducing the cognitive rigidity and social anxiety that have been shown to be important perpetuating factors in Anorexia Nervosa. Participants will be analysed to determine whether oxytocin brings about any improvements in thinking which might help patients with Anorexia Nervosa to recover more easily.
Query!
Trial website
Query!
Trial related presentations / publications
Maguire, S., O'Dell, A., Touyz, S., & Russell, J. 2013. Oxytocin and Anorexia Nervosa: A review of the Emerging Literature. European Eating Disorders Review, 21, 475-478. Workshop entitled 'Making Our Treatments Work (Better): Neuropsychology, Neuroendocrine and Cognitive Understandings and Strategies to Enhance Treatment for Anorexia Nervosa' Janice Russell, MD, FAED, Australia at the International Conference on Eating Disorders, March 2014, New York.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
32755
0
Prof Janice Russell
Query!
Address
32755
0
The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorder, The University of Sydney Ground Floor, Medical Foundation Bldg (K25) 92-94 Parramatta Road Camperdown, NSW 2006
Query!
Country
32755
0
Australia
Query!
Phone
32755
0
+61 2 97362288
Query!
Fax
32755
0
Query!
Email
32755
0
[email protected]
Query!
Contact person for public queries
Name
16002
0
Lauren Touyz
Query!
Address
16002
0
The Boden Institute, The University of Sydney
Ground Floor, Medical Foundation Building (K25)
92-94 Parramatta Rd
Camperdown NSW 2050
Query!
Country
16002
0
Australia
Query!
Phone
16002
0
+61 2 90363069
Query!
Fax
16002
0
+61 2 90363176
Query!
Email
16002
0
[email protected]
Query!
Contact person for scientific queries
Name
6930
0
Lauren Touyz
Query!
Address
6930
0
The Boden Institute, The University of Sydney
Ground Floor, Medical Foundation Building (K25)
92-94 Parramatta Rd
Camperdown NSW 2050
Query!
Country
6930
0
Australia
Query!
Phone
6930
0
+61 2 90363069
Query!
Fax
6930
0
Query!
Email
6930
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding.
2018
https://dx.doi.org/10.1016/j.psyneuen.2017.10.014
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF